Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Hodi, Frank Stephen; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean-Jacques; Rutkowski, Piotr; Cowey, Charles Lance; Lao, Christopher D; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Ferrucci, Pier Francesco; Smylie, Michael; Hill, Andrew; Hogg, David; Marquez-Rodas, Ivan; Jiang, Joel; Rizzo, Jasmine; Larkin, James; Wolchok, Jedd D (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology:1-13.

Wolchok, Jedd D; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C Lance; Lao, Christopher D; Wagstaff, John; Schadendorf, Dirk; Ferrucci, Pier F; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; Haanen, John; Carlino, Matteo S; et al (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14):1345-1356.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.

This list was generated on Wed Jun 19 01:47:20 2019 CEST.